drugset / Trial / NCT01131325

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

NCT01131325

Phase 4 Terminated 3 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

This study is to determine the number of European Leukemia Network (ELN)guideline defined treatment failure events from time of study entry in CML-CP patients with low imatinib trough concentrations treated with nilotinib.

Timeline

Start
2010-10-21
Primary completion
2011-05-12
Completion
2011-05-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Nilotinib Small molecule 300 mg Oral